
Daniel Auclair/X
Jun 15, 2025, 08:11
Daniel Auclair: Impressive Early Data Presented at EHA2025 for JNJ’4496 Dual CD19/CD20 CART in R/R LBCL
Daniel Auclair, President at Hematocure, LLC shared a post on X:
“Impressive early data presented for JNJ’4496 dual CD19/CD20 CART in R/R LBCL at EHA2025. 100% ORR and 80% CR at RP2D. No Gr. 3/4 CRS to date, no prophylactic therapy for ICANS or CRS.”
More posts featuring EHA 2025 on OncoDaily.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Jun 15, 2025, 07:04
Jun 15, 2025, 06:41
Jun 15, 2025, 05:57
Jun 15, 2025, 05:47
Jun 15, 2025, 05:32
Jun 15, 2025, 02:23